Skip to main content
. 2019 Oct 30;12:8863–8871. doi: 10.2147/OTT.S225760

Table 3.

Clinical Efficacies Of EGFR-TKIs For SqCLC Patients With EGFR Mutations

Author Total Cases ORR DCR mPFS (Months) mOS (Months)
Amit Joshi et al20 19 26.3% 47.3% 5 6.6
Cho et al18 12 50% 75% 3.67 30.23
Liu et al31 44 43.2% 77.3% 5.1 17.2
Xu et al32 26 30.8% 73.1% 3.98 NA
Our study 24 28.6% 78.6% 4.7 10.6

Abbreviations: ORR, overall response rate; DCR, disease control rate; mPFS, median progression-free survival; mOS, median overall survival.